U.S. markets closed
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • Dow 30

    34,935.47
    -149.03 (-0.42%)
     
  • Nasdaq

    14,672.68
    -105.62 (-0.71%)
     
  • Russell 2000

    2,226.25
    -13.78 (-0.62%)
     
  • Crude Oil

    73.81
    +0.19 (+0.26%)
     
  • Gold

    1,812.50
    -18.70 (-1.02%)
     
  • Silver

    25.55
    -0.23 (-0.90%)
     
  • EUR/USD

    1.1872
    -0.0024 (-0.20%)
     
  • 10-Yr Bond

    1.2390
    -0.0300 (-2.36%)
     
  • GBP/USD

    1.3908
    -0.0050 (-0.35%)
     
  • USD/JPY

    109.6500
    +0.1890 (+0.17%)
     
  • BTC-USD

    41,131.24
    -232.93 (-0.56%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • Nikkei 225

    27,283.59
    -498.81 (-1.80%)
     

Galecto's GB0139 Shows Favorable Safety In COVID-19 Patients, But Plans To Focus On Fibrosis, Cancer Programs

·1 min read
  • Amid the continued evolution of the COVID-19 landscape, Galecto Inc (NASDAQ: GLTO) said it would focus on the Phase 2 pipeline of fibrosis and cancer treatments, despite announcing positive preliminary topline results from an investigator-initiated trial examining GB0139 in COVID-19.

  • The trial included 41 hospitalized patients who did not require mechanical ventilation, of which 20 were randomized to the GB0139 arm.

  • GB0139 showed a favorable safety profile with no treatment-related serious adverse events reported.

  • GB0139 had a positive trend on acute lung injury related to COVID-19. Patients who received GB0139 showed improved lung function with a significant decline in oxygen flow requirements than patients only receiving standard of care (SOC).

  • Patients showed improved inflammation and coagulation biomarkers.

  • In a posthoc subgroup analysis of patients with moderate to severe COVID-19 infection, there was a 21% reduction in mortality in patients treated with GB0139 vs. SOC.

  • Price Action: GLTO shares are down 3.49% at $4.70 during the market trading session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.